Caerulein and secretin induced pancreatic growth: a possible control by endogenous pancreatic somatostatin.
Pancreatic hypertrophy and hyperplasia following chronic joint (CA + SE), or separate, caerulein (CA: 1 microgram . kg-1) and secretin (SE: 75 micrograms . kg-1) administration were studied in parallel with pancreatic somatostatin (SRIF) contents following 2, 4, 7 and 10 days of treatment. Parameters indicative of pancreatic growth (tissue weight, DNA and protein contents, cellular protein concentrations) increased significantly after 2 days of CA or CA + SE and reached a plateau between days 4 and 10. SE merely induced a mild hypertrophy after 4 days. Endogenous pancreatic SRIF contents varied upon treatment, differently so with each peptide regimen. Indeed, CA and CA + SE treatments decreased total SRIF contents after 2 days with no effect thereafter. SE also decreased the latter after 2 days while significant increases were observed after 7 and 10 days. The inverse relationship seemingly existing between SRIF contents and the amplitude of hormonally-induced pancreatic growth supports the hypothesis that endogenous pancreatic SRIF, operating as an 'antigrowth' factor, may participate in the exogenous CA, SE and CA + SE stimulated pancreatic growth phenomena.
Sarfati
P D
PD
Genik
P
P
Morisset
J
J
D000818:Animals; D002108:Ceruletide / Q000494:pharmacology*; D004247:DNA / Q000032:analysis; D004347:Drug Interactions; D006965:Hyperplasia; D006984:Hypertrophy; D008297:Male; D009929:Organ Size / Q000187:drug effects; D010179:Pancreas / Q000187:drug effects / Q000473:pathology*; D051381:Rats; D011919:Rats, Inbred Strains; D012633:Secretin / Q000494:pharmacology*; D013004:Somatostatin / Q000502:physiology*
D012633:Secretin; D013004:Somatostatin; D002108:Ceruletide; D004247:DNA